Patient Characteristics
Of Confirm Rx devices implanted in the U.S. between April 2018 and March
2020, 1,000 devices were randomly selected in June 2020 (48.5% male,
age 71 [61, 78] years). Of those, 869 devices with at least 90 days
of transmission history were included in the analysis. Of those 869
devices, 644 devices transmitted a total of 95,716 arrhythmia EGMs, 177
devices transmitted only symptom EGMs, and the remaining 48 devices
transmitted no EGMs. The number of EGMs corresponding to each arrhythmia
type, and the number of devices that transmitted those EGMs, are
provided in Table 1 . The 644 devices associated with at least
one arrhythmia EGM transmitted 4.1 [0.7, 19.3] EGMs/patient/month of
all arrhythmia types across a follow-up duration of 8.1 [5.5, 10.9]
months, for a total of 34.0 [5.0, 141.5] EGMs/patient. The patient
distribution by reason for monitoring is provided in Table 2 .
Devices were predominantly implanted due to syncope (34.3%), suspected
AF (22.0%), or cryptogenic stroke (18.6%).